Senator Jorg Drager, Head of the State Ministry of Science and Research, City of Hamburg:
"Establishing the European ScreeningPort in Hamburg is an important milestone in the development of the life science cluster in northern Germany. Together with our partners, the Federal Ministry of Education and Research and Evotec AG, we are building a state-of-the-art research infrastructure from which universities in Germany and beyond will be able to benefit. Having this infrastructure for scientist to develop drug candidates for innovative therapeutics in place is a huge success for our scientific region and proof of the good work conducted by Norgenta, the cluster agency of Hamburg and Schleswig-Holstein."
Jorn Aldag, President & Chief Executive Officer of Evotec AG:
"We know from our many years of experience as a leading European partner in drug discovery for pharmaceutical and biotech companies worldwide, and from our own research on diseases of the Central Nervous System that academic research generates a plethora of excellent scientific ideas that require an industrial environment for further development. The initial step in this development is the search to identify biologically active chemical compounds. The European ScreeningPort provides us with the link that translates scientific discoveries into results that pharmaceutical and biotechnological companies, such as Evotec, can build upon."
Dr Kathrin Adlkofer, Managing Director of the North German Life Science Agency Norgenta:
"Our main objective is to bring together existing excellence in science and business. ScreeningPort will see a unique network of partners in academia and industry who will mutually be able to benefit from pooling their expertise in medical science, technological know-how and industrial performance."
Press office of the German Federal Ministry of Education and Research
|SOURCE Evotec AG|
Copyright©2007 PR Newswire.
All rights reserved